An update on primary drug therapies for Alzheimer disease

David S Knopman, John C. Morris

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Propelled by remarkable advances in the understanding of the pathological characteristics of Alzheimer disease (AD), the prospects for the treatment of the clinical disorder have brightened considerably in the past decade. Primary treatment is aimed at the core elements of AD: memory and other cognitive loss at the symptomatic level and the pathological characteristics of molecular, cellular, and neural systems at the biological level. Behavioral features, such as depression, delusions, anxiety, disordered sleep, and agitation, are considered secondary manifestations of AD, although these features have a major impact on the quality of life, functional effectiveness, and caregiver burden. The focus of this review is on recent developments in the primary therapy for AD.

Original languageEnglish (US)
Pages (from-to)1406-1409
Number of pages4
JournalArchives of Neurology
Volume54
Issue number11
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Alzheimer Disease
Drug Therapy
Delusions
Caregivers
Sleep
Therapeutics
Anxiety
Quality of Life
Depression
Alzheimer's Disease
Drugs
Therapy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

An update on primary drug therapies for Alzheimer disease. / Knopman, David S; Morris, John C.

In: Archives of Neurology, Vol. 54, No. 11, 11.1997, p. 1406-1409.

Research output: Contribution to journalArticle

Knopman, David S ; Morris, John C. / An update on primary drug therapies for Alzheimer disease. In: Archives of Neurology. 1997 ; Vol. 54, No. 11. pp. 1406-1409.
@article{c7752ac41b5a42789b2921ed0e1a1d2d,
title = "An update on primary drug therapies for Alzheimer disease",
abstract = "Propelled by remarkable advances in the understanding of the pathological characteristics of Alzheimer disease (AD), the prospects for the treatment of the clinical disorder have brightened considerably in the past decade. Primary treatment is aimed at the core elements of AD: memory and other cognitive loss at the symptomatic level and the pathological characteristics of molecular, cellular, and neural systems at the biological level. Behavioral features, such as depression, delusions, anxiety, disordered sleep, and agitation, are considered secondary manifestations of AD, although these features have a major impact on the quality of life, functional effectiveness, and caregiver burden. The focus of this review is on recent developments in the primary therapy for AD.",
author = "Knopman, {David S} and Morris, {John C.}",
year = "1997",
month = "11",
language = "English (US)",
volume = "54",
pages = "1406--1409",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - An update on primary drug therapies for Alzheimer disease

AU - Knopman, David S

AU - Morris, John C.

PY - 1997/11

Y1 - 1997/11

N2 - Propelled by remarkable advances in the understanding of the pathological characteristics of Alzheimer disease (AD), the prospects for the treatment of the clinical disorder have brightened considerably in the past decade. Primary treatment is aimed at the core elements of AD: memory and other cognitive loss at the symptomatic level and the pathological characteristics of molecular, cellular, and neural systems at the biological level. Behavioral features, such as depression, delusions, anxiety, disordered sleep, and agitation, are considered secondary manifestations of AD, although these features have a major impact on the quality of life, functional effectiveness, and caregiver burden. The focus of this review is on recent developments in the primary therapy for AD.

AB - Propelled by remarkable advances in the understanding of the pathological characteristics of Alzheimer disease (AD), the prospects for the treatment of the clinical disorder have brightened considerably in the past decade. Primary treatment is aimed at the core elements of AD: memory and other cognitive loss at the symptomatic level and the pathological characteristics of molecular, cellular, and neural systems at the biological level. Behavioral features, such as depression, delusions, anxiety, disordered sleep, and agitation, are considered secondary manifestations of AD, although these features have a major impact on the quality of life, functional effectiveness, and caregiver burden. The focus of this review is on recent developments in the primary therapy for AD.

UR - http://www.scopus.com/inward/record.url?scp=0030730113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030730113&partnerID=8YFLogxK

M3 - Article

C2 - 9362990

AN - SCOPUS:0030730113

VL - 54

SP - 1406

EP - 1409

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -